📰 Access Pathway News
Page 9 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
June 9, 2023
Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.
June 9, 2023
FinancialContent fully hosted finance channel
June 8, 2023
STOCKHOLM, June 8, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab
June 8, 2023
/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application...
June 8, 2023
TOKYO and CAMBRIDGE, Mass., June 8, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization application for lecanemab (brand
June 1, 2023
The Pharmaceutical Journal from the Royal Pharmaceutical Society
May 30, 2023
The research conducted at Cedar Clinical Research in Draper is part of the first ever phase 3 program of psilocybin therapy, and the largest of its kind VANCOUVER, BC, May 30, 2023 /PRNewswire/ -... | May 30, 2023
May 26, 2023
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study,... | May 26, 2023
May 26, 2023
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study, conducted
May 26, 2023
New recognition routes will facilitate faster access to innovative medicines through seven international partners, according to UK’s MHRA.